<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822288</url>
  </required_header>
  <id_info>
    <org_study_id>101080-F</org_study_id>
    <nct_id>NCT01822288</nct_id>
  </id_info>
  <brief_title>The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder</brief_title>
  <official_title>The Impact of Different Hormone Therapy Regimens on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Menopausal syndromes includes somatic symptom, psychosomatic symptoms, sexual dysfunction and
      even urinary symptoms. Hormone therapy (HT) is widely used for controlling menopausal
      symptoms. Common HT for menopausal syndrome with intact uterus includes tibolone, estradiol
      valerate (E2V) 1mg &amp; medroxyprogesterone acetate (MPA) 2.5 mg, and conjugated equine
      estrogens &amp; MPA.

      However, only a few literatures mentioned about the therapeutic effect of tibolone, but lack
      of comparison research about their therapeutic effect on somatic symptoms, psychosomatic
      symptoms, sexual dysfunction and even urinary symptoms. The knowledge of the above
      therapeutic effects should be important for choosing a suitable medication. Therefore, the
      aim of this study is to assess the therapeutic effect on somatic symptoms, psychosomatic
      symptoms, sexual dysfunction and even urinary symptoms between tibolone and E2V/MPA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menopausal symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>To clarify any difference of reduction in menopausal symptom scores between these two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sexual function</measure>
    <time_frame>12 weeks</time_frame>
    <description>To clarify any difference of improvements of sexual function scores between these two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lower urinary tract symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>To clarify any difference of improvements of lower urinary tract symptoms scores between these two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>psychosomatic symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>To clarify any difference of improvements of psychosomatic symptoms scores between these two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Menopausal Syndromes</condition>
  <arm_group>
    <arm_group_label>Tibolone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tibolone (2.5 mg per day)for 12 consecutive weeks. Tibolone should be paid by patient herself, and does not cover by Taiwan Government health insurance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional hormone therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estradiol valerate (E2V) 1mg &amp; medroxyprogesterone acetate (MPA) 2.5 mg per day for 12 consecutive weeks, and this drug is paid by Taiwan Government health care insurance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tibolone</intervention_name>
    <description>Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)</description>
    <arm_group_label>Tibolone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol &amp; medroxyprogesterone acetate</intervention_name>
    <description>Estradiol &amp; medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug</description>
    <arm_group_label>Conventional hormone therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All female patients with intact uterus who seek for medical treatment for menopausal
             syndrome

        Exclusion Criteria:

          -  patients with gynecologic or breast cancers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Banqiao Dist., New Taipei</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Mou Hsiao, M.D.</last_name>
      <phone>+886-2-89667000</phone>
      <phone_ext>1424</phone_ext>
      <email>smhsiao2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sheng-Mou Hsiao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2013</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Sheng-Mou Hsiao</investigator_full_name>
    <investigator_title>Chief, Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>Tibolone</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Hormone therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Psychophysiologic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Tibolone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

